Results 241 to 250 of about 50,491,421 (329)

Editorial Team

Drug Analytical Research, 2019
- Drug Analytical Research
doaj  

A Conversation with Nasser Altorki, MD, David B. Skinner, M.D. Professor of Thoracic Surgery, Weill Cornell Medicine

Journal of Clinical and Translational Science
Clinical Research Forum
doaj   +1 more source

Prioritising opportunities to strengthen the maternal, newborn, and child health research ecosystem in Ethiopia: a Delphi exercise. [PDF]

J Glob Health
Taddesse L, Korte ML, Hunegnaw BM, Teklie H, Bekele D, Tolera G, Zelalem M, Chan GJ.   +7 more
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Population data on Finland 1900-1985

Finnish Yearbook of Population Research, 1986
Population Research Institute
doaj  

Conversation Barriers and Strategies Used by People With Parkinson's and Their Partners to Support Conversation. [PDF]

Int J Lang Commun Disord
Thilakaratne R, Wylie K, Loftus AM, Cocks N.   +3 more
europepmc   +1 more source

Hearings for hearing...cenzura morum? [PDF]

, 2002
Research, Update
core  

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

A conversation with Kevin Gibbs, MD, associate professor, Wake Forest University School of Medicine

Journal of Clinical and Translational Science
Clinical Research Forum
doaj   +1 more source

Research/Researchers [PDF]

MRS Bulletin, 1996
openaire   +1 more source